Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10870MR)

This product GTTS-WQ10870MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Melanoma, Neuroblastoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10870MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7701MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ3564MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ15039MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SRF-231
GTTS-WQ1105MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ10117MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ8298MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ14370MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ10800MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M777-16-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW